SSX2 and synovial sarcoma: While disruption of normal BAF complex function is central in synovial sarcoma, studies in mice have shown that SMARCB1 loss is not required for SS18-SSX-driven tumorigenesis, generating instead tumors with epithelioid sarcoma features16,18.